[{"address1": "333 Lakeside Drive", "city": "Foster City", "state": "CA", "zip": "94404", "country": "United States", "phone": "650 574 3000", "fax": "650 578 9264", "website": "https://www.gilead.com", "industry": "Drug Manufacturers\u2014General", "sector": "Healthcare", "longBusinessSummary": "Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, Sunlencs, and Atripla products for the treatment of HIV/AIDS; Veklury, an injection for intravenous use, for the treatment of COVID-19; and Epclusa, Harvoni, Vemlidy, and Viread for the treatment of viral hepatitis. It also offers Yescarta, Tecartus, and Trodelvy products for the treatment of oncology; Letairis, an oral formulation for the treatment of pulmonary arterial hypertension; and AmBisome, a liposomal formulation for the treatment of serious invasive fungal infections. The company has collaboration agreements with Arcus Biosciences, Inc.; Merck Sharp & Dohme Corp.; Pionyr Immunotherapeutics Inc.; Tizona Therapeutics, Inc.; Galapagos NV; Janssen Sciences Ireland Unlimited Company; Japan Tobacco, Inc.; Dragonfly Therapeutics, Inc.; Arcellx, Inc.; Everest Medicines; Merck & Co, Inc.; Tentarix Biotherapeutics Inc.; and Assembly Biosciences, Inc. It also has research collaboration, option, and license agreement with Merus N.V. for the discovery of novel dual tumor-associated antigens (TAA) targeting trispecific antibodies. The company was incorporated in 1987 and is headquartered in Foster City, California.", "fullTimeEmployees": 18000, "companyOfficers": [{"maxAge": 1, "name": "Mr. Daniel P.  O'Day", "age": 59, "title": "Chairman & CEO", "yearBorn": 1964, "fiscalYear": 2023, "totalPay": 6992634, "exercisedValue": 0, "unexercisedValue": 13201385}, {"maxAge": 1, "name": "Mr. Andrew D. Dickinson", "age": 53, "title": "Chief Financial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 2664586, "exercisedValue": 0, "unexercisedValue": 5999063}, {"maxAge": 1, "name": "Ms. Deborah H. Telman", "age": 58, "title": "Executive VP of Corporate Affairs, General Counsel & Corporate Secretary", "yearBorn": 1965, "fiscalYear": 2023, "totalPay": 2563013, "exercisedValue": 0, "unexercisedValue": 307810}, {"maxAge": 1, "name": "Ms. Johanna  Mercier", "age": 53, "title": "Chief Commercial Officer", "yearBorn": 1970, "fiscalYear": 2023, "totalPay": 3096055, "exercisedValue": 0, "unexercisedValue": 5530527}, {"maxAge": 1, "name": "Dr. Merdad V. Parsey M.D., Ph.D.", "age": 60, "title": "Chief Medical Officer", "yearBorn": 1963, "fiscalYear": 2023, "totalPay": 2792095, "exercisedValue": 0, "unexercisedValue": 4919564}, {"maxAge": 1, "name": "Ms. Sandra  Patterson", "age": 56, "title": "Senior VP, Corporate Controller & Principal Accounting Officer", "yearBorn": 1967, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jacquie  Ross C.F.A.", "title": "Vice President of Investor Relations", "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Jyoti K. Mehra", "age": 46, "title": "Executive Vice President of Human Resources", "yearBorn": 1977, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Linda Slanec Higgins Ph.D.", "age": 61, "title": "Senior Vice President of Research, Innovation & Portfolio", "yearBorn": 1962, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Rudolf  Ertl", "age": 77, "title": "Senior Vice President of Commercial Operations of Australia, Canada, Europe", "yearBorn": 1946, "fiscalYear": 2023, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 4, "boardRisk": 5, "compensationRisk": 4, "shareHolderRightsRisk": 1, "overallRisk": 2, "governanceEpochDate": 1725148800, "compensationAsOfEpochDate": 1703980800, "maxAge": 86400, "priceHint": 2, "previousClose": 79.13, "open": 78.95, "dayLow": 77.74, "dayHigh": 79.32, "regularMarketPreviousClose": 79.13, "regularMarketOpen": 78.95, "regularMarketDayLow": 77.74, "regularMarketDayHigh": 79.32, "dividendRate": 3.08, "dividendYield": 0.038900003, "exDividendDate": 1726185600, "payoutRatio": 3.7073002, "fiveYearAvgDividendYield": 4.03, "beta": 0.196, "trailingPE": 96.060974, "forwardPE": 10.970752, "volume": 4262535, "regularMarketVolume": 4262535, "averageVolume": 6989167, "averageVolume10days": 5454410, "averageDailyVolume10Day": 5454410, "bid": 78.7, "ask": 78.85, "bidSize": 200, "askSize": 400, "marketCap": 98067857408, "fiftyTwoWeekLow": 62.07, "fiftyTwoWeekHigh": 87.87, "priceToSalesTrailing12Months": 3.5269864, "fiftyDayAverage": 73.5288, "twoHundredDayAverage": 73.2211, "trailingAnnualDividendRate": 3.04, "trailingAnnualDividendYield": 0.038417794, "currency": "USD", "enterpriseValue": 118001221632, "profitMargins": 0.03791, "floatShares": 1242589246, "sharesOutstanding": 1244989952, "sharesShort": 16765272, "sharesShortPriorMonth": 21250019, "sharesShortPreviousMonthDate": 1721001600, "dateShortInterest": 1723680000, "sharesPercentSharesOut": 0.0135, "heldPercentInsiders": 0.0011999999, "heldPercentInstitutions": 0.879, "shortRatio": 2.61, "shortPercentOfFloat": 0.0135, "bookValue": 14.672, "priceToBook": 5.368729, "lastFiscalYearEnd": 1703980800, "nextFiscalYearEnd": 1735603200, "mostRecentQuarter": 1719705600, "earningsQuarterlyGrowth": 0.545, "netIncomeToCommon": 1054000000, "trailingEps": 0.82, "forwardEps": 7.18, "pegRatio": 3.45, "lastSplitFactor": "2:1", "lastSplitDate": 1359331200, "enterpriseToRevenue": 4.244, "enterpriseToEbitda": 8.766, "exchange": "NMS", "quoteType": "EQUITY", "symbol": "GILD", "underlyingSymbol": "GILD", "shortName": "Gilead Sciences, Inc.", "longName": "Gilead Sciences, Inc.", "firstTradeDateEpochUtc": 696090600, "timeZoneFullName": "America/New_York", "timeZoneShortName": "EDT", "uuid": "8659e669-8ec5-3b0f-9929-db5db506231f", "gmtOffSetMilliseconds": -14400000, "currentPrice": 78.77, "targetHighPrice": 119.0, "targetLowPrice": 68.5, "targetMeanPrice": 82.29, "targetMedianPrice": 79.5, "recommendationMean": 2.5, "recommendationKey": "buy", "numberOfAnalystOpinions": 26, "totalCash": 3780999936, "totalCashPerShare": 3.037, "ebitda": 13461999616, "totalDebt": 23349999616, "quickRatio": 0.783, "currentRatio": 1.142, "totalRevenue": 27804999680, "debtToEquity": 128.318, "revenuePerShare": 22.298, "returnOnAssets": 0.11545, "returnOnEquity": 0.05263, "freeCashflow": 6791249920, "operatingCashflow": 7468000256, "earningsGrowth": 0.554, "revenueGrowth": 0.054, "grossMargins": 0.77443004, "ebitdaMargins": 0.48416, "operatingMargins": 0.38717, "financialCurrency": "USD", "trailingPegRatio": 0.4687, "__fetch_time": "2024-09-05"}]